# Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

> **NCT05910801** · PHASE2 · RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 100 (estimated)

## Conditions studied

- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Lenalidomide
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Tafasitamab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05910801
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-04
- **Primary completion:** 2029-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910801, "Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05910801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*